Q32 Bio (QTTB) Liabilities and Shareholders Equity (2017 - 2026)
Q32 Bio (QTTB) posted quarterly Liabilities and Shareholders Equity of $63.7 million for Q1 2026, down 19.47% year-over-year from $79.1 million in Q1 2025, and up 3.07% quarter-over-quarter from $61.8 million in Q4 2025.
Q32 Bio (QTTB) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
Q32 Bio's Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $63.7 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 19.47% year-over-year to $63.7 million; the TTM figure through Mar 2026 stood at $249.4 million (down 37.69% YoY), while the FY2025 annual figure was $61.8 million, down 33.09% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $63.7 million, up from $61.8 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $311.0 million in Q1 2022, with the low at $47.1 million in Q4 2023.
- The 5-year median for Liabilities and Shareholders Equity is $124.2 million (2024), against an average of $143.7 million.
- The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity plunged 79.4% in 2023, then jumped 96.21% in 2024.
- Q32 Bio's Liabilities and Shareholders Equity stood at $228.5 million in 2022, then slumped by 79.4% to $47.1 million in 2023, then jumped by 96.21% to $92.3 million in 2024, then slumped by 33.09% to $61.8 million in 2025, then advanced by 3.07% to $63.7 million in 2026.
- Business Quant data shows QTTB's Liabilities and Shareholders Equity at $63.7 million in Q1 2026, $61.8 million in Q4 2025, and $57.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Q32 Bio | 359.61 Mn | 253.31 Mn | - | 115.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 115.87 Mn |
| Mar 31, 2026 | 63.68 Mn |
| Dec 31, 2025 | 61.78 Mn |
| Sep 30, 2025 | 57.78 Mn |
| Jun 30, 2025 | 66.12 Mn |
| Mar 31, 2025 | 79.07 Mn |
| Dec 31, 2024 | 92.33 Mn |
| Sep 30, 2024 | 104.54 Mn |
| Jun 30, 2024 | 124.21 Mn |
| Mar 31, 2024 | 152.33 Mn |
| Dec 31, 2023 | 47.06 Mn |
| Sep 30, 2023 | 140.06 Mn |
| Jun 30, 2023 | 169.34 Mn |
| Mar 31, 2023 | 197.88 Mn |
| Dec 31, 2022 | 228.47 Mn |
| Sep 30, 2022 | 262.65 Mn |
| Jun 30, 2022 | 284.61 Mn |
| Mar 31, 2022 | 310.96 Mn |
| Dec 31, 2021 | 211.72 Mn |
| Sep 30, 2021 | 230.82 Mn |